Navigation Links
Lexapro Loses First-Line Position for the Treatment of Major Depression
Date:5/12/2009

Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources

Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles

WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major depression. Lexapro may have lost its first-line dominance because of the increasing frequency of step therapy restrictions requiring patients to first try therapy with citalopram (Forest Laboratories' Celexa, generics) before being reimbursed for Lexapro.

The new report entitled Treatment Algorithms in Major Depression also finds that although atypical antipsychotics do not capture substantial patient share until the third-line of therapy in newly diagnosed patients, third-line patient share has grown from 11.8 percent to 17.1 percent since last year's report. This growth is likely attributed to physicians' growing comfort with these agents given the FDA approval of Bristol-Myers Squibb/Otsuka's Abilify as an adjunct therapy in 2007 and the expected upcoming FDA approval of AstraZeneca's Seroquel XR for treating this disease.

"AstraZeneca's Seroquel, Pfizer's Geodon and Eli Lilly's Zyprexa all capture more patient share in the third line in our current analysis versus the analysis in our 2008 report. Even though these agents are not FDA-approved for major depression, physicians appear to be becoming more comfortable with atypicals as a class, a trend that may reflect a spill-over effect from Abilify's approval," stated Michael Malecki, Ph.D., analyst at Decision Resources.

By pairing patient-level claims data with primary survey data, the report can be used to build patient-flow m
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
2. Zoloft, Lexapro the Best of Newer Antidepressants
3. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
4. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. HEI, Inc. Closes on Sale of RFID Division Assets
7. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
8. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
9. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
10. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
11. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... Watching action shows on TV may be bad for your ... snack food while watching action films and programs than something ... find that if you,re watching an action movie while snacking ... Tal, of the Cornell Food and Brand Lab, said in ... the program is, the more you will eat." The ...
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... York, NY (PRWEB) September 01, 2014 ... have been added to a federal litigation that continues ... South Carolina, Bernstein Liebhard LLP reports. , A ... claims now filed over the widely-used cholesterol medication by ... the drug. According to claims, Pfizer Inc. failed to ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... patients who do not respond to traditional therapy can ... transplant, according to an Indiana University School of Medicine ... England Journal of Medicine. , About 90 percent ... involves multiple courses of cisplatin, first used successfully in ...
... are urgently needed to reduce climate-altering carbon emissions that ... the World Health Organisation said Monday. ,Climate change ... in the region, according to WHO estimates. ,"So ... If the trend continues, it may have an impact on ...
... for tougher regulations on tobacco, as officials from 145 ... global efforts to stop smoking. ,The ... aims to find ways of harmonising national laws to ... from second-hand smoke. ,Hatai Chitanondh, the president ...
... who have difficulty recognizing familiar smells could be experiencing an ... Monday. ,Scientists already know that the first ... in an area of the brain that is home to ... Center in Chicago tested 589 people aged between 54 to ...
... Idaho in US had a miraculous escape while traveling by an ... the pilot last Wednesday from Twin Falls, Idaho, to Seattle when ... at a height of 20,000 ft. ,Rapid decompression occurred ... water bottle. Fogg's head and right arm were pulled outside the ...
... New York based Columbia University Medical Center has shown that ... form of alcohol use disorder at some point in ... the adults surveyed reported experiencing alcohol abuse, and 12.5 per ... an article published in the Archives of General Psychiatry, one ...
Cached Medicine News:Health News:Advanced therapy offers cure for relapsed cancer patient 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2Health News:Nurse Has Miraculous Escape as Window is Blown Off an Air Ambulance 2Health News:One-third of Adults Have Had Some Form of Alcohol Use Disorder During Their Lifetimes 2
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
... Nebulizer Small Volume Medication Mouthpiece 7FT O 2 ... ,An advanced jet design for fast treatment times ... with a tighter distribution (higher percentage of respirable ... ,Our AirLife™ brand Misty Max 10™ disposable nebulizers ...
Medicine Products: